Sarkar ne Indian-made coronary stents ki safety ko lekar investigation ke order diye hain. Sri Lanka mein kuch devices ke fail hone ke baad ye step uthaya gaya hai, jisse domestic medical sector mein quality norms aur tight ho sakte hain.
Investigation kyun shuru hui?
Union Health Ministry ne Indian-made coronary stents ki quality aur safety ko lekar formal investigation start kar di hai. Ye order October 5 ko Cabinet Secretariat ke direction par aaya hai. Asal mein, Sri Lanka ke market se kuch 'drug-eluting stents' ko withdraw kiya gaya tha kyunki unke perform karne mein issues aa rahe the, jaise ki artery mein thik se expand na hona ya device ka dislodge hona. Ab sarkar inhi claims ki deep investigation kar rahi hai.
Kya badal sakta hai rules mein?
Central Drugs Standard Control Organisation (CDSCO) pehle se hi Medical Devices Rules, 2017 ke under industry ko standardize karne ki koshish kar rahi hai. Ab focus 'traceability' par hai. Sarkar chahti hai ki har stent ka batch aur serial number track ho sake taaki agar koi faulty product ho toh use turant identify kiya ja sake.
Investors aur Companies ke liye kya hai catch?
Producers ke liye iska matlab hai badhta hua operational cost. Agar naye guidelines aate hain, toh companies ko apni manufacturing line aur quality control ko aur upar uthana hoga. Saath hi, ministry ab international alerts ko bhi India ke monitoring system ke sath link karne wali hai, jiska matlab hai ki global failures ka asar ab domestic compliance par tezi se dikhega. Investors ko ab is baat par nazar rakhni hogi ki companies apne margins ko kaise manage karti hain jab ye naye safety mandates laagu honge.